Hubbry Logo
StreptococcusStreptococcusMain
Open search
Streptococcus
Community hub
Streptococcus
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Streptococcus
Streptococcus
Streptococcus
View on Wikipedia
from Wikipedia

Streptococcus
Scientific classification Edit this classification
Domain: Bacteria
Kingdom: Bacillati
Phylum: Bacillota
Class: Bacilli
Order: Lactobacillales
Family: Streptococcaceae
Genus: Streptococcus
Rosenbach, 1884
Species[1]

Streptococcus, from Ancient Greek στρεπτός (streptós), meaning "twisted", and κόκκος (kókkos), meaning "grain", is a genus of gram-positive spherical bacteria that belongs to the family Streptococcaceae, within the order Lactobacillales (lactic acid bacteria), in the phylum Bacillota.[2] Cell division in streptococci occurs along a single axis, thus when growing they tend to form pairs or chains, which may appear bent or twisted. This differs from staphylococci, which divide along multiple axes, thereby generating irregular, grape-like clusters of cells. Most streptococci are oxidase-negative and catalase-negative, and many are facultative anaerobes (capable of growth both aerobically and anaerobically).

The term was coined in 1877 by Viennese surgeon Albert Theodor Billroth (1829–1894),[3] from Ancient Greek στρεπτός (streptós), meaning "twisted"[4], and κόκκος (kókkos), meaning "grain"[5]. In 1984, many bacteria formerly grouped in the genus Streptococcus were separated out into the genera Enterococcus and Lactococcus.[6] Currently, over 50 species are recognised in this genus. This genus has been found to be part of the salivary microbiome.[7]

Pathogenesis and classification

[edit]
See also: Streptococcosis

In addition to streptococcal pharyngitis (strep throat), certain Streptococcus species are responsible for many cases of pink eye,[8] meningitis, bacterial pneumonia, endocarditis, erysipelas, and necrotizing fasciitis (the 'flesh-eating' bacterial infections). However, many streptococcal species are not pathogenic, and form part of the commensal human microbiota of the mouth, skin, intestine, and upper respiratory tract. Streptococci are also a necessary ingredient in producing Emmentaler ("Swiss") cheese.[9]

Species of streptococci are classified based on their hemolytic properties.[10] Alpha-hemolytic species cause oxidization of iron in hemoglobin molecules within red blood cells, giving it a greenish color on blood agar. Beta-hemolytic species cause complete rupture of red blood cells. On blood agar, this appears as wide areas clear of blood cells surrounding bacterial colonies. Gamma-hemolytic species cause no hemolysis.[11]

Beta-hemolytic streptococci are further classified by Lancefield grouping, a serotype classification (that is, describing specific carbohydrates present on the bacterial cell wall).[6] The 21 described serotypes are named Lancefield groups A to W (excluding E, I and J). This system of classification was developed by Rebecca Lancefield, a scientist at Rockefeller University.[12]

In the medical setting, the most important groups are the alpha-hemolytic streptococci S. pneumoniae and Streptococcus viridans groups, and the beta-hemolytic streptococci of Lancefield groups A and B (also known as "group A strep" and "group B strep").

Table: Medically relevant streptococci[10]

Species Host Disease
S. pyogenes human pharyngitis, cellulitis, erysipelas
S. agalactiae human, cattle neonatal meningitis and sepsis
S. dysgalactiae human, animals endocarditis, bacteremia, pneumonia, meningitis, respiratory infections
S. gallolyticus human, animals biliary or urinary tract infections, endocarditis
S. anginosus human, animals subcutaneous/organ abscesses, meningitis, respiratory infections
S. sanguinis human endocarditis, dental caries
S. suis swine meningitis
S. mitis human endocarditis
S. mutans human dental caries
S. pneumoniae human pneumonia

Alpha-hemolytic

[edit]

When alpha-hemolysis (α-hemolysis) is present, a blood based agar under the colony will appear dark and greenish due to the conversion of hemoglobin to green biliverdin. Streptococcus pneumoniae and a group of oral streptococci (Streptococcus viridans or viridans streptococci) display alpha-hemolysis. Alpha-hemolysis is also termed incomplete hemolysis or partial hemolysis because the cell membranes of the red blood cells are left intact. This is also sometimes called green hemolysis because of the color change in the agar.[citation needed]

Pneumococci

[edit]
  • S. pneumoniae (sometimes called pneumococcus), is a leading cause of bacterial pneumonia and the occasional etiology of otitis media, sinusitis, meningitis, and peritonitis. Inflammation is thought to be the major cause of how pneumococci cause disease, hence the tendency of diagnoses associated with them to involve inflammation. They possess no Lancefield antigens.[2]

The viridans group: alpha-hemolytic

[edit]

Beta-hemolytic

[edit]

Beta-hemolysis (β-hemolysis), sometimes called complete hemolysis, is a complete lysis of red cells in the media around and under the colonies: the area appears lightened (yellow) and transparent. Streptolysin, an exotoxin, is the enzyme produced by the bacteria which causes the complete lysis of red blood cells. There are two types of streptolysin: Streptolysin O (SLO) and streptolysin S (SLS). Streptolysin O is an oxygen-sensitive cytotoxin, secreted by most group A Streptococcus (GAS), and interacts with cholesterol in the membrane of eukaryotic cells (mainly red and white blood cells, macrophages, and platelets), and usually results in beta-hemolysis under the surface of blood agar. Streptolysin S is an oxygen-stable cytotoxin also produced by most GAS strains which results in clearing on the surface of blood agar. SLS affects immune cells, including polymorphonuclear leukocytes and lymphocytes, and is thought to prevent the host immune system from clearing infection. Streptococcus pyogenes, or GAS, displays beta hemolysis.

Some weakly beta-hemolytic species cause intense hemolysis when grown together with a strain of Staphylococcus. This is called the CAMP test. Streptococcus agalactiae displays this property. Clostridium perfringens can be identified presumptively with this test. Listeria monocytogenes is also positive on sheep's blood agar.

Alpha-hemolytic S. viridans (right) and beta-hemolytic S. pyogenes (left) streptococci growing on blood agar

Group A

[edit]

Group A S. pyogenes is the causative agent in a wide range of group A streptococcal infections (GAS). These infections may be noninvasive or invasive. The noninvasive infections tend to be more common and less severe. The most common of these infections include streptococcal pharyngitis (strep throat) and impetigo.[13] Scarlet fever is another example of Group A noninvasive infection.

The invasive infections caused by group A beta-hemolytic streptococci tend to be more severe and less common. This occurs when the bacterium is able to infect areas where it is not usually found, such as the blood and organs.[14] The diseases that may be caused include streptococcal toxic shock syndrome, necrotizing fasciitis, pneumonia, and bacteremia.[13] Globally, GAS has been estimated to cause more than 500,000 deaths every year, making it one of the world's leading pathogens.[13]

Additional complications may be caused by GAS, namely acute rheumatic fever and acute glomerulonephritis. Rheumatic fever, a disease that affects the joints, kidneys, and heart valves, is a consequence of untreated strep A infection caused not by the bacterium itself, but due to the antibodies created by the immune system to fight off the infection cross-reacting with other proteins in the body. This "cross-reaction" causes the body to essentially attack itself and leads to the damage above. A similar autoimmune mechanism initiated by Group A beta-hemolytic streptococcal (GABHS) infection is hypothesized to cause pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), wherein autoimmune antibodies affect the basal ganglia, causing rapid onset of psychiatric, motor, sleep, and other symptoms in pediatric patients.

GAS infection is generally diagnosed with a rapid strep test or by culture.

Group B

[edit]

S. agalactiae, or group B streptococcus, GBS, causes pneumonia and meningitis in newborns and the elderly, with occasional systemic bacteremia. Importantly, Streptococcus agalactiae is the most common cause of meningitis in infants from one month to three months old. They can also colonize the intestines and the female reproductive tract, increasing the risk for premature rupture of membranes during pregnancy, and transmission of the organism to the infant. The American College of Obstetricians and Gynecologists, American Academy of Pediatrics, and the Centers for Disease Control recommend all pregnant women between 35 and 37 weeks gestation to be tested for GBS. Women who test positive should be given prophylactic antibiotics during labor, which will usually prevent transmission to the infant.[15] Group III polysaccharide vaccines have been proven effective in preventing the passing of GBS from mother to infant.[16]

The United Kingdom has chosen to adopt a risk factor-based protocol, rather than the culture-based protocol followed in the US.[17] Current guidelines state that if one or more of the following risk factors is present, then the woman should be treated with intrapartum antibiotics:

  • GBS bacteriuria during this pregnancy
  • History of GBS disease in a previous infant
  • Intrapartum fever (≥38 °C)
  • Preterm labour (<37 weeks)
  • Prolonged rupture of membranes (>18 hours)

This protocol results in the administration of intrapartum antibiotics to 15–20% of pregnant women and the prevention of 65–70% of cases of early onset GBS sepsis.[18]

Group C

[edit]

This group includes S. equi, which causes strangles in horses,[19] and S. zooepidemicus — S. equi is a clonal descendant or biovar of the ancestral S. zooepidemicus — which causes infections in several species of mammals, including cattle and horses. S. dysgalactiae subsp. dysgalactiae[20] is also a member of group C, beta-haemolytic streptococci that can cause pharyngitis and other pyogenic infections similar to group A streptococci. Group C streptococcal bacteria are considered zoonotic pathogens, meaning infection can be passed from animal to human.[21]

Group D (enterococci)

[edit]

Many former group D streptococci have been reclassified and placed in the genus Enterococcus (including E. faecalis, E. faecium, E. durans, and E. avium).[22] For example, Streptococcus faecalis is now Enterococcus faecalis. E. faecalis is sometimes alpha-hemolytic and E. faecium is sometimes beta hemolytic.[23]

The remaining nonenterococcal group D strains include Streptococcus gallolyticus, Streptococcus bovis, Streptococcus equinus and Streptococcus suis.

Nonhemolytic streptococci rarely cause illness. However, weakly hemolytic group D beta-hemolytic streptococci and Listeria monocytogenes (which is actually a gram-positive bacillus) should not be confused with nonhemolytic streptococci.

Group F streptococci

[edit]

Group F streptococci were first described in 1934 by Long and Bliss among the "minute haemolytic streptococci".[24] They are also known as Streptococcus anginosus (according to the Lancefield classification system) or as members of the S. milleri group (according to the European system).

Group G streptococci

[edit]

These streptococci are usually, but not exclusively, beta-hemolytic. Streptococcus dysgalactiae subsp. canis[20] is the predominant subspecies encountered. It is a particularly common GGS in humans, although it is typically found on animals. S. phocae is a GGS subspecies that has been found in marine mammals and marine fish species. In marine mammals it has been mainly associated with meningoencephalitis, sepsis, and endocarditis, but is also associated with many other pathologies. Its environmental reservoir and means of transmission in marine mammals is not well characterized. Group G streptococci are also considered zoonotic pathogens.

Group H streptococci

[edit]

Group H streptococci cause infections in medium-sized canines. Group H streptococci rarely cause human illness unless a human has direct contact with the mouth of a canine. One of the most common ways this can be spread is human-to-canine, mouth-to-mouth contact. However, the canine may lick the human's hand and infection can be spread, as well.[25]

Clinical identification

[edit]
Example of a workup algorithm of possible bacterial infection in cases with no specifically requested targets (non-bacteria, mycobacteria etc.), with most common situations and agents seen in a New England setting. Main Streptococcus groups are included as "Strep." at bottom left.

In clinical practice, the most common groups of Streptococcus can be distinguished by simple bench tests, such as the PYR test for group A streptococcus. There are also latex agglutination kits which can distinguish each of the main groups seen in clinical practice.

Treatment

[edit]

Streptococcal infections can be treated with antibiotics from the penicillin family. Most commonly, penicillin or amoxicillin is used to treat strep infection. These antibiotics work by disrupting peptidoglycan production in the cell wall.[26] Treatment most often occurs as a 10-day oral antibiotic cycle. For patients with penicillin allergies and those suffering from skin infections, clindamycin can be used. Clindamycin works by disrupting protein synthesis within the cell.

Molecular taxonomy and phylogenetics

[edit]
Phylogenetic tree of Streptococcus species, based on data from PATRIC.[27] 16S groups are indicated by brackets and their key members are highlighted in red.

Streptococci have been divided into six groups on the basis of their 16S rDNA sequences: S. anginosus, S. gallolyticus, S. mitis, S. mutans, S. pyogenes and S. salivarius.[28] The 16S groups have been confirmed by whole genome sequencing (see figure). The important pathogens S. pneumoniae and S. pyogenes belong to the S. mitis and S. pyogenes groups, respectively,[29] while the causative agent of dental caries, Streptococcus mutans, is basal to the Streptococcus group.

A conceptual diagram of Streptococcus subclade taxonomy based on phylogenetic trees and the conserved signature indels (CSIs) that are specifically shared by groups of streptococci.[30] The number of CSIs identified for each group is shown.

Recent technological advances have resulted in an increase of available genome sequences for Streptococcus species, allowing for more robust and reliable phylogenetic and comparative genomic analyses to be conducted.[30] In 2018, the evolutionary relationships within Streptococcus was re-examined by Patel and Gupta through the analysis of comprehensive phylogenetic trees constructed based on four different datasets of proteins and the identification of 134 highly specific molecular signatures (in the form of conserved signature indels) that are exclusively shared by the entire genus or its distinct subclades.[30]

The results revealed the presence of two main clades at the highest level within Streptococcus, termed the "Mitis-Suis" and "Pyogenes-Equinus-Mutans" clades.[30] The "Mitis-Suis" main clade comprises the Suis subclade and the Mitis clade, which encompasses the Angiosus, Pneumoniae, Gordonii and Parasanguinis subclades. The second main clade, the "Pyogenes-Equinus-Mutans", includes the Pyogenes, Mutans, Salivarius, Equinus, Sobrinus, Halotolerans, Porci, Entericus and Orisratti subclades. In total, 14 distinct subclades have been identified within the genus Streptococcus, each supported by reliable branching patterns in phylogenetic trees and by the presence of multiple conserved signature indels in different proteins that are distinctive characteristics of the members of these 14 clades.[30] A summary diagram showing the overall relationships among the Streptococcus based on these studies is depicted in a figure on this page.

Genomics

[edit]
Common and species-specific genes among Streptococcus sanguinis, S. mutans, and S. pneumoniae. Modified after Xu et al. (2007)[31]

The genomes of hundreds of species have been sequenced.[32] Most Streptococcus genomes are 1.8 to 2.3 Mb in size and encode 1,700 to 2,300 proteins. Some important genomes are listed in the table.[33] The four species shown in the table (S. pyogenes, S. agalactiae, S. pneumoniae, and S. mutans) have an average pairwise protein sequence identity of about 70%.[33]

feature S. pyogenes S. agalactiae S. pneumoniae S. mutans
base pairs 1,852,442 2,211,488 2,160,837 2,030,921
ORFs 1792 2118 2236 1963
prophages yes no no no

Bacteriophage

[edit]

Bacteriophages have been described for many species of Streptococcus. 18 prophages have been described in S. pneumoniae that range in size from 38 to 41 kb in size, encoding from 42 to 66 genes each.[34] Some of the first Streptococcus phages discovered were Dp-1[35][36] and ω1 (alias ω-1).[37][38][39] In 1981 the Cp (Complutense phage 1, officially Streptococcus virus Cp1, Picovirinae) family was discovered with Cp-1 as its first member.[40] Dp-1 and Cp-1 infect both S. pneumoniae and S. mitis.[41] However, the host ranges of most Streptococcus phages have not been investigated systematically.

Natural genetic transformation

[edit]

Natural genetic transformation involves the transfer of DNA from one bacterium to another through the surrounding medium. Transformation is a complex process dependent on the expression of numerous genes. To be capable of transformation a bacterium must enter a special physiologic state referred to as competence. S. pneumoniae, S. mitis and S. oralis can become competent, and as a result actively acquire homologous DNA for transformation by a predatory fratricidal mechanism [42] This fratricidal mechanism mainly exploits non-competent siblings present in the same niche [43] Among highly competent isolates of S. pneumoniae, Li et al.[44] showed that nasal colonization fitness and virulence (lung infectivity) depend on an intact competence system. Competence may allow the streptococcal pathogen to use external homologous DNA for recombinational repair of DNA damages caused by the host's oxidative attack.[45]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Streptococcus

View on Grokipedia
from Grokipedia
Streptococcus is a of characterized by spherical cocci that typically occur in pairs (diplococci) or chains, are nonmotile and non-sporeforming, and are generally catalase-negative facultative anaerobes. The name derives from the Greek words streptos (chain) and kokkos (berry), reflecting their chained arrangement under the , and was coined by Austrian surgeon in 1874 to describe organisms observed in wound infections and . These require enriched media for growth, such as blood agar, where they exhibit distinct hemolytic patterns—beta-hemolysis (complete clearing), alpha-hemolysis (partial greening), or gamma-hemolysis (none)—and some species produce capsules, notably in Group A streptococci. The genus encompasses over 50 species and several subspecies, classified primarily into Lancefield groups (A through V) based on cell wall carbohydrate antigens, though not all species fit this scheme. Notable species include Streptococcus pyogenes (Group A), S. agalactiae (Group B), S. pneumoniae (pneumococcus), and various viridans group streptococci, with some like enterococci formerly included but now reclassified. Streptococci inhabit diverse niches as commensal organisms in the human and animal microbiota, colonizing sites such as the nasopharynx, oral cavity, skin, and gastrointestinal tract, while certain species are exclusively human pathogens or zoonotic agents. For instance, oral streptococci like S. mutans are early colonizers of the mouth acquired post-birth, contributing to the normal flora but also implicated in dental caries through biofilm formation. Medically, Streptococcus species are of profound importance due to their role in a spectrum of infections ranging from mild to life-threatening, with approximately 35 species capable of causing invasive . S. pyogenes is a leading cause of bacterial (strep throat), , skin infections like and , and severe conditions such as streptococcal , resulting in over 500,000 deaths annually worldwide; recent surveillance data indicate a significant increase in invasive infections, with incidence more than doubling in the United States from 2013 to 2022 and reaching a 20-year high in 2023 (as of 2024). S. pneumoniae primarily causes , , and otitis media, accounting for approximately 300,000 deaths in children under five each year (as of 2024), while S. agalactiae is a major neonatal leading to and . is driven by factors including capsules for immune evasion, hemolysins like streptolysin O, M proteins for antiphagocytic activity, and enzymes such as . Beyond , streptococci contribute to post-infectious immune-mediated diseases like and , and some species serve industrial roles in fermentation (e.g., cheese and production) and as indicators of fecal pollution in .

Introduction and History

Definition and Significance

Streptococcus is a of consisting of spherical cells, or cocci, that typically arrange in pairs or chains and are facultatively anaerobic, belonging to the phylum . These nonmotile, nonsporeforming microbes are catalase-negative and often identified initially by their hemolytic patterns on blood agar, such as alpha- or beta-hemolysis. Approximately 126 are currently recognized within the genus as of 2024, encompassing a diverse range of commensal, opportunistic, and pathogenic organisms. Medically, Streptococcus holds significant importance due to its role in human infections, with many species acting as opportunistic pathogens that cause substantial morbidity and mortality. Key examples include S. pyogenes (group A Streptococcus), which leads to , skin infections, and severe invasive diseases like , and S. pneumoniae, a primary cause of and . Globally, streptococcal diseases alone result in over 500,000 deaths annually, including from acute infections and long-term sequelae such as rheumatic heart disease. The burden is particularly acute in low-resource settings, where approximately 616 million cases of strep throat occur each year, contributing to over 300,000 deaths from invasive infections as of recent estimates. Beyond , Streptococcus contribute positively to and industry; they form a dominant component of the human oral , aiding in formation and . Certain strains, such as S. thermophilus, are essential in food fermentation processes, including and cheese production, enhancing flavor and texture through generation. Economically, streptococcal infections impose a heavy toll, with U.S. healthcare and productivity costs for Streptococcus exceeding $5 billion annually, underscoring the need for improved prevention and treatment strategies.

Discovery and Historical Milestones

The genus Streptococcus was first described in 1874 by Austrian surgeon , who observed chain-forming bacteria in pus from wound infections and cases during his studies at the . Billroth's microscopic observations marked the initial recognition of these organisms as distinct pathogens associated with surgical infections, though he did not formally name the genus at that time. In 1884, German physician Friedrich Julius Rosenbach refined the nomenclature by naming based on isolates from purulent wounds, emphasizing the pus-forming (pyogenes) nature of the chain-like (streptos) bacteria. Concurrently, in the 1880s, and George Sternberg independently identified as the causative agent of through experiments involving saliva injections in rabbits, establishing its role in respiratory infections. These early isolations shifted perceptions from vague "pus organisms" to specific streptococcal species linked to human disease. A pivotal advancement came in 1933 when Rebecca C. Lancefield introduced serological grouping based on cell wall carbohydrate antigens, classifying hemolytic streptococci into groups (e.g., A for S. pyogenes) to differentiate human pathogens from animal-associated strains. This system, expanded in 1935, enabled precise epidemiological tracking and remains foundational for identifying virulence potential. The saw further evolution from viewing streptococci as a uniform group to recognizing a diverse , exemplified by Alexander Fleming's 1928 , which produced a substance inhibiting streptococcal growth and revolutionized treatment of infections like and puerperal sepsis by the 1940s. In 2018, a comprehensive phylogenetic re-analysis of 70 Streptococcus genomes delineated 14 distinct subclades, incorporating four established groups and six novel ones, providing a genomic framework that refined historical classifications and highlighted evolutionary diversity. Recent taxonomic updates as of 2025 have added four novel from the human oral cavity, further expanding the .

Taxonomy and Classification

Traditional Phenotypic Classification

The traditional phenotypic classification of Streptococcus species relies on observable characteristics such as hemolytic reactions on blood agar, serological grouping based on cell wall antigens, and biochemical tests, which were foundational before molecular methods emerged. This system, developed in the early , categorizes streptococci primarily into hemolytic groups and serological groups to aid in identification and differentiation, particularly for clinically relevant pathogens. Hemolytic classification, introduced by Schottmüller in 1903, distinguishes streptococci based on their effects on red cells in sheep plates. Alpha-hemolytic streptococci produce partial , resulting in a greenish discoloration around colonies due to the production of and reduced . Beta-hemolytic streptococci cause complete , forming clear zones around colonies from the action of hemolysins like streptolysin O and S. Gamma-hemolytic (or non-hemolytic) streptococci show no , appearing as opaque colonies without zones. This differentiation is not always reliable, as hemolytic patterns can vary with media composition, incubation conditions, or strain differences. The Lancefield serological grouping system, established by Rebecca Lancefield in 1933, further refines classification by detecting specific carbohydrate antigens in the bacterial cell wall using antisera. Groups are designated A through H (and beyond to V for some species), with streptococci featuring a polyrhamnose backbone with side chains, and identified by glucosyl-rhamnose polymers. For instance, most beta-hemolytic streptococci fall into groups A (e.g., S. pyogenes), B (S. agalactiae), C, or G, while group D includes strains that hydrolyze esculin. This method involves extracting the antigen via acid or enzyme treatment and precipitating it with group-specific antibodies, enabling rapid serological identification. Additional phenotypic traits commonly used in classification include consistent biochemical properties shared across streptococci. All species are catalase-negative, distinguishing them from staphylococci, and most are facultative anaerobes capable of growth in both aerobic and anaerobic conditions, though some like S. mutans prefer microaerophilic environments. patterns also aid grouping; for example, group D streptococci ferment and , while does not ferment . These traits, assessed via tests like bile-esculin or broths, complement and for preliminary identification. Despite its utility, the traditional phenotypic system has notable limitations, including phenotypic overlap and potential misclassification. For instance, enterococci were initially classified as group D streptococci due to shared fermentation traits but were reclassified into a separate in the based on genetic differences, highlighting the system's inability to resolve evolutionary relationships. Variability in expression and in serological tests can lead to errors, particularly for non-beta-hemolytic strains, prompting the adoption of phylogenetic methods for more precise .

Modern Phylogenetic Classification

The modern phylogenetic classification of Streptococcus relies primarily on molecular techniques such as 16S rRNA gene sequencing and multi-locus sequence typing (MLST), which enable precise delineation of evolutionary relationships by analyzing conserved ribosomal RNA genes and multiple housekeeping loci, respectively. These methods have revealed a diverse genus encompassing 139 validly published species as of November 2025, reflecting ongoing genomic discoveries and taxonomic refinements. A pivotal phylogenomic study utilizing core genome sequences from 70 Streptococcus type strains robustly demarcated the genus into 14 distinct species groups, providing a genome-based framework that surpasses earlier phenotypic groupings in resolution and stability. These groups include the well-established pyogenic (e.g., S. pyogenes), bovis (S. gallolyticus), mutans (S. mutans), salivarius (S. salivarius), and anginosus (S. anginosus) clades, alongside nine additional subclades that highlight finer evolutionary divergences within the . This core genome approach, focusing on shared orthologous genes, has informed subsequent classifications by emphasizing genetic cohesion over traditional patterns. Recent genomic surveys have expanded the with novel , such as S. wuxiensis, S. jiangnanensis, and S. fermentans, all isolated from human in 2025 and positioned within the salivarius group via 16S rRNA and whole-genome analyses. Similarly, S. shenyangsis, described in 2021 from the oropharynx of a healthy , clusters closely with the mitis group based on MLST and 16S rRNA phylogenies, underscoring the 's association with human mucosal niches. Significant reclassifications have shaped the genus's boundaries; notably, in 1984, genomic DNA hybridization studies led to the separation of Enterococcus (e.g., E. faecalis) from Streptococcus due to distinct phylogenetic positions and phenotypic traits like growth in high-salt environments. Ongoing debates persist regarding S. suis, a porcine pathogen with zoonotic potential, as phylogenomic analyses reveal divergent clades that challenge its monophyletic placement, with some strains showing closer affinity to related species like S. parasuis based on average nucleotide identity thresholds below 95%. These discussions highlight the need for integrated multi-omic approaches to resolve ambiguous boundaries within the genus.

Biology and Physiology

Cellular Structure and Morphology

Streptococci are Gram-positive cocci measuring 0.5 to 2.0 μm in diameter, typically appearing spherical or ovoid and arranged in pairs (diplococci) or chains due to division in a single plane. These possess a thick that retains the stain during Gram staining, distinguishing them from Gram-negative organisms. Species such as are round-to-ovoid with diameters of 0.6-1.0 μm, while often exhibits a lancet-shaped diplococcal form measuring 0.5-1.25 μm. The cell wall of streptococci consists primarily of a thick peptidoglycan layer composed of repeating units of and N-acetylmuramic acid, cross-linked by bridges to provide structural rigidity. Embedded within this layer are wall teichoic acids, which are anionic covalently linked to the peptidoglycan via phosphodiester bonds to muramic acid residues, and lipoteichoic acids, which anchor to the cytoplasmic membrane and extend into the wall to link proteins. Many pathogenic species, such as S. pneumoniae, produce a capsule surrounding the ; this capsule comprises over 100 serotypes of repeating saccharide units attached to the peptidoglycan (as of 2025). In S. pyogenes, the capsule is composed of , a non-antigenic that contributes to the smooth . Internally, streptococci lack spores and contain a single circular that encodes essential genetic information, with some strains harboring plasmids that confer antibiotic resistance. Variations in morphology can occur; for instance, older cultures may show pleomorphism or loss of Gram positivity, and S. pneumoniae can form short chains in certain growth conditions, with colonies displaying central depressions due to autolysis. Electron microscopy reveals the as a 30-40 nm electron-dense band with a surrounding low-density layer of 60-80 nm in S. pneumoniae.

Growth Requirements and Metabolism

Streptococci are facultative anaerobes capable of growth in the presence or absence of oxygen, though most species exhibit aerotolerance rather than strict aerophily. Optimal growth occurs at temperatures between 35°C and 37°C, reflecting their adaptation to , with incubation periods typically requiring 18 to 24 hours for visible colony formation on solid media. The preferred pH range is neutral to slightly alkaline, around 7.0 to 7.5, as seen in standard blood agar formulations where deviations can inhibit hemolytic reactions and overall proliferation. Due to their fastidious nature, streptococci necessitate enriched media such as tryptic soy agar supplemented with 5% sheep blood or Todd-Hewitt broth with , which provide essential peptides and complex nutrients absent in minimal media. Metabolically, streptococci rely on fermentative pathways for energy production, predominantly through homolactic where glucose is converted to via the Embden-Meyerhof-Parnas (glycolytic) pathway, yielding two molecules of ATP per glucose molecule through . This process involves phosphoenolpyruvate-dependent phosphotransferase systems (PTS) for sugar uptake and phosphorylation, enabling efficient carbohydrate utilization in nutrient-variable environments. While most species, such as and , are homolactic under anaerobic or low-oxygen conditions, some exhibit mixed-acid fermentation (producing , , and alongside lactate) when exposed to higher oxygen levels, reflecting metabolic flexibility. Heterofermentative , involving the production of additional byproducts like CO₂, is less common but observed in certain oral species. Streptococci lack complete respiratory chains and , precluding aerobic respiration unless exogenous is supplied. Nutritionally, streptococci are auxotrophic for numerous —often up to 15 or more, including and cystine—and require exogenous sources of vitamins such as NAD, which they salvage via salvage pathways rather than . They are incapable of , relying on host-derived factors for any limited respiratory capabilities in supplemented conditions, and depend on oligopeptide permeases for uptake to meet protein synthesis demands. This fastidiousness underscores their adaptation to nutrient-rich host niches, where complex media mimicking blood or tissue fluids support robust growth. Regarding oxygen sensitivity, while aerotolerant due to enzymes like and NADH oxidases, prolonged exposure to high oxygen levels can generate that impair viability; capnophilic species like S. pneumoniae show enhanced growth under 5% to 10% CO₂ atmospheres, which stabilizes and facilitates proliferation.

Ecology

Natural Habitats and Reservoirs

Streptococcus species are predominantly host-associated , primarily colonizing mucosal surfaces in humans and animals, though certain species occupy environmental niches such as products, , and . The encompasses over 50 adapted to diverse ecological roles, with most thriving in warm, nutrient-rich environments provided by animal hosts. These often form biofilms, such as in oral plaque, which enhances their persistence in natural settings. In humans, the oropharynx is a primary for the viridans group streptococci, which constitute a significant portion of the normal oral , with prevalence rates often exceeding 70% in healthy adults and approaching 98% in children. The skin and genital tract also serve as reservoirs, particularly for Streptococcus (), which colonizes the vaginal mucosa in 10-30% of non-pregnant women and higher rates during . These mucosal sites support , underscoring the commensal nature of many Streptococcus . Animal reservoirs are equally diverse, with predominantly inhabiting the nasopharynx and saliva of pigs, where it persists as a commensal in up to 100% of healthy swine herds. is a common resident in the udders of , causing bovine and serving as a reservoir linked to environments. In , such as Streptococcus catagoni have been isolated from the respiratory tracts of Chacoan peccaries (Catagonus wagneri), highlighting the genus's adaptation to non-domesticated mammals. Other examples include streptococci in marine mammals and , where aquatic environments may act as secondary reservoirs. Certain Streptococcus species extend beyond host associations into environmental habitats; for instance, is naturally found in and persists in dairy processing environments, contributing to fermented products like . Fecal streptococci, including some group D species, survive in and under moist conditions for weeks, indicating limited environmental persistence influenced by and . These non-host niches, while not primary, facilitate occasional transmission between reservoirs.

Commensal and Pathogenic Interactions

Streptococcus species often exist as commensals within host , contributing to microbial balance and providing protective functions against pathogens. Viridans group streptococci, primary colonizers of the oral cavity, produce and other antimicrobial substances that inhibit the growth of harmful bacteria such as Streptococcus mutans and , thereby preventing dental caries and . In the oral flora, these streptococci facilitate early formation that excludes pathogens through competitive adhesion and metabolic byproducts. Certain Streptococcus species, such as , also support digestive processes in the gut microbiome by aiding in the breakdown of complex carbohydrates and , promoting nutrient absorption and maintaining intestinal . However, under certain conditions, commensal Streptococcus can shift to opportunistic pathogens, particularly when the host is disrupted. Antibiotic treatment reduces microbial diversity, allowing overgrowth of Streptococcus species like Streptococcus agalactiae in the gut, which can lead to invasive infections by outcompeting beneficial . formation by streptococci further enhances this opportunism, enabling communities to evade host immune responses through reduced and complement activation, as seen in respiratory tract of Streptococcus pneumoniae. Host factors significantly influence the transition from to in Streptococcus interactions. Immunocompromised states, including those from chronic diseases or immunosuppressive therapies, heighten susceptibility to streptococcal overgrowth and by impairing mucosal barriers and innate immunity. In the elderly, age-related exacerbates this risk, with higher incidence of due to diminished T-cell responses and reduced in the respiratory tract. Ecological dynamics within microbiomes underscore the competitive nature of Streptococcus with other , shaping community stability. Streptococci engage in resource and produce natural products like to suppress rivals such as Veillonella species in oral biofilms, maintaining ecological equilibrium. Recent 2025 research highlights how enrichment of in respiratory boosts innate immunity via modulation, potentially protecting against viral infections like by altering microbial .

Key Species

Streptococcus pyogenes (Group A)

Streptococcus pyogenes, commonly referred to as (GAS), is a gram-positive, beta-hemolytic coccus that grows in chains or pairs and is classified in Lancefield based on its specific carbohydrate antigen. This bacterium exhibits complete on blood agar, producing clear zones around colonies due to the action of oxygen-labile streptolysin O and oxygen-stable streptolysin S. A hallmark is the protein, a coiled-coil surface protein that inhibits by binding to host complement regulators and mimicking human proteins, thereby evading innate immune responses. Over 220 emm types have been identified through sequencing of the emm gene, which encodes the hypervariable N-terminal region of the M protein; these types vary in geographic distribution and are associated with different disease severities, with emm1 and emm3 often linked to invasive infections. Epidemiologically, S. pyogenes maintains pharyngeal carriage in 5-15% of the general , with higher rates among children aged 5-15 years in crowded or low-socioeconomic settings, serving as a for transmission. Following the , global has documented an uptick in invasive GAS diseases since 2020, with notable surges in cases and severity reported in , the , and , potentially influenced by reduced immunity during lockdowns. A 2025 study from identified a novel mutation in the fhuB gene of emm89 strains, which disrupts iron uptake and is associated with enhanced in severe invasive infections, particularly in Japanese isolates; this , absent in non-severe strains, highlights evolving pathogenicity. Unique to S. pyogenes are its secreted toxins, including streptolysins O and S, which lyse host cells and erythrocytes to promote tissue and immune evasion, and multiple DNases (e.g., streptodornase A-F) that hydrolyze to facilitate bacterial dissemination. These factors contribute to its capacity to cause , a rapidly progressive characterized by toxin-mediated and systemic toxicity. Vaccine development efforts advanced in 2025 with preclinical evaluation of an mRNA-lipid platform encoding five conserved antigens—streptococcal C5a peptidase, streptolysin O, SpyCEP, deiminase, and trigger factor—demonstrating robust and protection in murine and models against diverse GAS strains. Although primarily a pathogen with no established animal reservoirs, rare isolations from animals such as rabbits and sheep suggest occasional zoonotic transmission from human carriers.

Streptococcus agalactiae (Group B)

Streptococcus agalactiae, commonly known as Streptococcus (GBS), is a beta-hemolytic gram-positive bacterium characterized by its Lancefield carbohydrate , a peptidoglycan-anchored structure that distinguishes it from other streptococci. This species produces a capsule that enables into 10 serotypes (Ia, Ib, II–IX) based on structural variations in the capsular , which play a key role in immune evasion and . Additionally, S. agalactiae expresses surface proteins, including members of the Ibc family (such as the Alpha C protein), which contribute to adherence and host interaction. As a member of the beta-hemolytic streptococci, it exhibits complete on blood agar, often enhanced by synergistic effects with other hemolysins. Epidemiologically, S. agalactiae colonizes the vaginal and rectal mucosa of 10–30% of pregnant women asymptomatically, serving as the primary reservoir for to newborns. This carriage rate facilitates its role as the leading cause of early-onset and , with a global incidence of invasive disease estimated at 0.49 cases per 1,000 live births. In neonatal contexts, transmission typically occurs during labor, underscoring the bacterium's significance in perinatal infections. A distinctive feature of S. agalactiae is the CAMP factor, a pore-forming cytolytic protein that enhances through synergistic activity with sphingomyelinase C from , producing a characteristic arrowhead pattern on blood agar. Regarding vaccine development, progress in 2025 includes ongoing Phase II trials of a 6-valent glycoconjugate (GBS6) targeting major capsular serotypes (Ia, Ib, II, III, IV, V) for administration to pregnant women, aiming to induce protective transplacental antibodies against neonatal disease. Preclinical studies have demonstrated robust serotype-specific IgG responses with this approach. In , S. agalactiae is a primary etiological agent of bovine , causing significant economic losses in dairy herds through intramammary infections that lead to reduced milk production and quality. Evidence suggests zoonotic potential, with genomic analyses indicating shared isolates between human and bovine strains, raising concerns for interspecies transmission.

Streptococcus pneumoniae

Streptococcus pneumoniae is a Gram-positive, alpha-hemolytic bacterium characterized by its lancet-shaped diplococci morphology, often appearing in pairs under microscopic examination. This encapsulated pathogen is facultatively anaerobic and a major cause of respiratory infections, with its polysaccharide capsule playing a key role in evading host immunity. The species exhibits over 100 distinct capsular serotypes, which vary in virulence and prevalence; the 23-valent pneumococcal polysaccharide vaccine (PPSV23) targets 23 of these serotypes to provide protection against invasive disease. Epidemiologically, S. pneumoniae colonizes the nasopharynx asymptomatically in approximately 5-10% of healthy adults, serving as a for transmission, though carriage rates are higher in children. Globally, it contributes to about 1.6 million deaths annually, predominantly from , with higher burdens in low-resource settings. A 2024 genomic study in revealed slow geographical migration dynamics of pneumococcal strains, taking up to 50 years for homogeneous mixing across regions due to focal transmission patterns influenced by mobility. This highlights the pathogen's evolutionary adaptation and the challenges in controlling its spread through alone. Distinctive features of S. pneumoniae include the Quellung reaction, a serological method using type-specific antisera to visualize capsule swelling under microscopy, which remains the gold standard for serotype identification. Additionally, the major autolysin LytA facilitates natural competence for genetic transformation by promoting cell lysis and DNA release during the competent state, aiding in horizontal gene transfer and antibiotic resistance evolution. Vaccination with conjugate vaccines like PCV13 and PCV21 has dramatically reduced invasive pneumococcal disease by approximately 70% in vaccinated populations, particularly through herd immunity effects. However, post-vaccination serotype replacement has occurred, with non-vaccine serotypes such as 6C, 12F, and 23B emerging and increasing in carriage and disease incidence.00588-7/fulltext)

Other Notable Species

The viridans group streptococci, comprising alpha-hemolytic species such as Streptococcus mutans and Streptococcus sanguinis, are primarily commensal inhabitants of the human oral cavity, where they contribute to the normal microbiota but can become opportunistic pathogens. These bacteria are notable for their role in infective endocarditis, particularly in patients with underlying heart conditions, as they can enter the bloodstream during dental procedures and adhere to damaged heart valves. S. mutans, in particular, is a key etiological agent in dental caries, producing acids that demineralize tooth enamel through fermentation of dietary carbohydrates. Formerly classified as Group D streptococci, species like (now reclassified as Streptococcus gallolyticus subsp. gallolyticus) were historically grouped with enterococci but are now recognized as distinct within the Streptococcus genus. This species is associated with bacteremia that signals underlying colorectal neoplasia, with studies showing that up to 60% of patients with S. gallolyticus infections harbor colonic tumors, prompting routine screening. Among emerging zoonotic species, stands out as a major veterinary pathogen causing meningitis, septicemia, and in pigs, with sporadic human infections reported predominantly in among those handling raw pork. Human cases often manifest as severe with hearing loss, and outbreaks have been documented in and , highlighting occupational risks in the swine industry. In 2025, novel species such as Streptococcus wuxiensis were isolated from , demonstrating potential as commensals that utilize human milk oligosaccharides to support development. These findings suggest probiotic-like roles in modulating early-life microbial ecosystems, though to confirm non-pathogenic status. Veterinarily significant species include Streptococcus equi subsp. equi, the causative agent of in horses, a highly contagious upper respiratory characterized by abscessation and fever. This disease affects worldwide, with vaccination and biosecurity measures essential for control. Beyond these, the genus encompasses approximately 20 additional non-pyogenic, non-bovis , many of which are commensal or host-specific with limited pathogenic potential in humans.

Factors

Streptococcus employ a diverse array of factors that enable to host tissues, toxin-mediated damage, immune evasion, and enzymatic facilitation of . These factors are predominantly surface-associated or secreted proteins and , contributing to the pathogen's ability to colonize and persist within the host. Adhesins in Streptococcus promote initial attachment to mucosal surfaces and extracellular matrix components. The M protein, a coiled-coil surface fibrillar protein primarily in Streptococcus pyogenes (Group A Streptococcus), binds to host receptors such as CD46 on keratinocytes and fibrinogen, facilitating bacterial adherence and inhibiting opsonization. Pili, long filamentous structures encoded by distinct genetic islands, mediate tight adhesion to host epithelial cells and collagen; for instance, in S. pyogenes and S. agalactiae, they enhance colonization of pharyngeal and vaginal mucosa, respectively. Toxins produced by Streptococcus directly damage host cells and modulate immune responses. Streptolysin O and S are pore-forming cytolysins that disrupt plasma membranes of erythrocytes, leukocytes, and endothelial cells; streptolysin O, a cholesterol-dependent , also suppresses and promotes activation. Superantigens, such as the streptococcal pyrogenic exotoxins () including SpeA and SpeC in S. pyogenes, bind T-cell receptors outside the antigen-binding groove, causing massive release and . Immune evasion strategies in Streptococcus counteract and antibody-mediated clearance. capsules, composed of in S. pyogenes or phosphorylcholine in S. pneumoniae, form a protective barrier that inhibits complement deposition and recognition, significantly enhancing survival in blood. Proteinases like IdeS (immunoglobulin G-degrading of S. pyogenes) specifically cleave the hinge region of human IgG, generating Fab and Fc fragments that impair opsonization and . degrade host in connective tissues, creating pathways for bacterial dissemination while also mimicking host structures to evade detection. Enzymes secreted by Streptococcus further support by degrading host defenses and promoting spread. Deoxyribonucleases (DNases), such as Sda1 in S. pyogenes, hydrolyze DNA in (NETs), preventing entrapment and killing of bacteria during . activates host plasminogen to , which dissolves fibrin clots and degrades , thereby facilitating bacterial invasion from localized sites.

Mechanisms

Streptococci initiate through colonization of host mucosal surfaces, primarily via adherence mechanisms mediated by surface structures such as pili and s. In species like and S. agalactiae, pili facilitate attachment to epithelial cells by interacting with host components, enabling initial binding and subsequent formation that protects the bacteria from host defenses and antibiotics. on the cell wall further promote adherence to and other host proteins, enhancing stable in areas like the or genital tract. development, influenced by teichoic acid modifications, allows streptococci to form structured communities that resist shear forces and immune clearance, as observed in S. mutans dental plaques and S. agalactiae vaginal persistence. Once colonized, streptococci invade deeper tissues using enzymes and protective structures to breach barriers and enter the bloodstream. , produced by S. pyogenes and S. agalactiae, depolymerizes in the , facilitating tissue penetration and promoting ascending infections, such as in group B streptococcal preterm labor models where it impairs function and enhances bacterial spread. The capsular (CPS) shields bacteria from , aiding survival during mucosal breaches that lead to bacteremia, particularly in S. pneumoniae where CPS variants correlate with invasive progression. This invasion process often transitions from localized infection to systemic dissemination via damaged . Streptococci modulate the host to evade clearance and exacerbate , notably through superantigens that trigger massive T-cell activation and storms. In S. pyogenes, superantigens like A (SPE-A) cross-link and T-cell receptors, leading to polyclonal T-cell proliferation and release of pro-inflammatory s such as TNF-α and IL-6, which contribute to . Additionally, streptolysin O induces in macrophages, suppressing phagocytic activity and allowing unchecked bacterial replication during invasive infections. These mechanisms collectively dampen adaptive immunity while amplifying innate inflammation, creating a favorable environment for persistence. Dissemination of streptococci occurs through fibrinolytic activity that dissolves clots and promotes vascular spread. Streptokinase activates host plasminogen to plasmin, enabling S. pyogenes to degrade fibrin barriers and escape immune-trapping clots, as demonstrated in models where bacteria remain viable within clots before utilizing plasminogen for fibrinolysis and deeper tissue invasion. This process facilitates hematogenous spread to distant sites, such as in necrotizing fasciitis. Recent genetic analyses in 2025 identified mutations in emm89 S. pyogenes strains that enhance invasiveness by altering regulatory pathways, contributing to increased invasive disease incidence post-pandemic.

Diseases Caused

Suppurative Infections

Suppurative infections caused by Streptococcus species involve direct bacterial invasion of tissues, leading to acute inflammation and pus formation. These infections primarily affect the , , soft tissues, and systemic sites, with (group A Streptococcus, or GAS) being the most common culprit in non-invasive and invasive cases among children and adults. Other species, such as (group B Streptococcus, or GBS) and , contribute to specific invasive syndromes. Clinical presentation often includes localized pain, fever, and , progressing to abscesses or deeper tissue destruction if untreated. Pharyngitis, or strep throat, is a hallmark suppurative infection caused by S. pyogenes, accounting for 15-30% of cases in children and 5-20% in adults. It manifests as sudden-onset sore throat, fever, pharyngeal exudate, and tender cervical lymphadenopathy, typically resolving within days but risking spread to deeper sites. A toxin-mediated complication is scarlet fever, where S. pyogenes strains producing erythrogenic toxins (superantigens SpeA, SpeC, or SpeJ) induce a characteristic "sandpaper" rash, strawberry tongue, and circumoral pallor following pharyngitis. This rash results from toxin-induced capillary dilation and inflammation, affecting the skin and mucous membranes. Skin and soft tissue infections by GAS range from superficial to life-threatening. presents as honey-crusted lesions on exposed skin, often in children, with bullous forms linked to exfoliative toxins. involves deeper dermal invasion, causing rapidly spreading , warmth, and , commonly following minor trauma or insect bites. , known as "flesh-eating disease," is a severe invasive form where GAS rapidly destroys subcutaneous tissues and , leading to bullae, , and systemic toxicity; mortality rates range from 20% to 60%, depending on delays in surgical and comorbidities. Invasive suppurative infections extend beyond local sites, causing bacteremia and organ involvement. GAS bacteremia often complicates skin or respiratory infections, leading to with high fever, , and multi-organ failure. GBS is a primary cause of puerperal sepsis in postpartum women, presenting as , bacteremia, or following , with rates of approximately 0.2–0.4 cases per 1,000 deliveries and associated maternal morbidity from uterine infection. S. pneumoniae induces , characterized by consolidation of an entire lobe on , productive , rust-colored , and pleuritic , predominantly in unvaccinated adults and children. Epidemiologically, GAS suppurative infections surged post-COVID-19 from 2022 onward into 2025, attributed to reduced population immunity from lockdowns and increased testing. In and , invasive GAS cases rose 2- to 5-fold in children and adults, with and skin infections driving outpatient visits and hospitalizations increasing by up to 50% in some regions. This upsurge highlights vulnerabilities in pediatric and elderly populations, prompting enhanced surveillance.

Non-Suppurative Sequelae

Non-suppurative sequelae of streptococcal infections are delayed, immune-mediated complications that arise without ongoing bacterial replication, primarily following group A Streptococcus (GAS) pharyngitis or skin infections. These conditions result from aberrant immune responses, such as molecular mimicry or immune complex deposition, leading to inflammation in distant organs like the heart, kidneys, and brain. Acute rheumatic fever (ARF) is a classic non-suppurative sequela occurring 2-4 weeks after untreated GAS pharyngitis, with an estimated risk of 0.3-3% in susceptible individuals. The pathogenesis involves molecular mimicry, where antibodies against the GAS M protein cross-react with cardiac myosin in heart valves and myocardium, triggering autoimmune carditis and potential progression to rheumatic heart disease (RHD). Clinical manifestations include migratory polyarthritis, carditis, chorea, subcutaneous nodules, and erythema marginatum, with carditis being the most serious feature affecting up to 60% of cases. Post-streptococcal (PSGN) develops 1-3 weeks after GAS infection, often from or , due to deposition of immune complexes containing streptococcal antigens in the renal glomeruli. These complexes activate complement and inflammatory pathways, causing glomerular inflammation, , , , and ; nephritogenic strains like M types 49 and 12 are commonly implicated. Unlike ARF, PSGN can follow skin infections more frequently and is generally self-limiting in children but may lead to in some adults. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections () represent a controversial but recognized entity where GAS triggers sudden-onset obsessive-compulsive disorder (OCD), tics, anxiety, and in genetically susceptible children aged 3-12 years. The mechanism likely involves autoantibodies crossing the blood-brain barrier to target neurons, mimicking anti-streptolysin O responses. Symptoms often remit with antibiotic treatment of the preceding infection but can recur with reinfections. Globally, these sequelae impose a heavy burden, particularly RHD, which affects an estimated 55 million people and causes approximately 360,000 deaths annually, with over 90% of cases occurring in low- and middle-income countries due to limited access to diagnostics and antibiotics. PSGN contributes to in endemic areas, while adds to pediatric challenges, underscoring the need for early intervention in streptococcal infections.

Diagnosis

Culture and Serological Methods

Streptococci are typically isolated from clinical specimens such as swabs, blood, or wound exudates using enriched media to support their fastidious growth. Primary cultivation occurs on blood agar plates, where the organisms produce characteristic hemolytic patterns after 24-48 hours of incubation at 37°C in 5% CO₂; beta-, indicated by clear zones around colonies, is observed in groups A, B, C, and G, while alpha- (partial with a greenish hue) is typical for . For Streptococcus (GBS), selective enrichment broths like LIM (Todd-Hewitt broth supplemented with and ) are used to suppress normal flora, followed by subculture onto sheep blood agar to enhance recovery rates up to 90% in screening scenarios. A key rapid diagnostic method for group A Streptococcus (GAS) pharyngitis is the rapid antigen detection test (RADT), which detects group A carbohydrate antigen directly from throat swabs. RADTs provide results in 5-15 minutes with specificity exceeding 95%, but sensitivity ranges from 70-95%, necessitating backup throat culture for negative results in children under IDSA guidelines to avoid missing infections. The 2025 Infectious Diseases Society of America (IDSA) guidelines recommend using a clinical scoring system, such as the modified , to assess patients and determine the need for testing, aiming to reduce unnecessary use by identifying low-risk cases. Identification begins with microscopic examination via Gram staining, revealing gram-positive cocci arranged in pairs or chains, a morphology consistent across streptococcal species. The test is negative for all streptococci, distinguishing them from staphylococci, as no bubbling occurs upon addition of . For presumptive identification of alpha-hemolytic streptococci as S. pneumoniae, optochin susceptibility testing uses a disk impregnated with ethylhydrocupreine ; a zone of inhibition ≥14 mm indicates sensitivity, with >95% specificity, while solubility tests confirm by rapid dissolution of colonies in 2-10% sodium deoxycholate due to autolysin activity. For Streptococcus (GAS), a bacitracin disk test is employed; GAS shows sensitivity with a zone of inhibition due to its lack of resistance to the , achieving specificity greater than 95% when combined with beta-hemolysis observation. Serological methods, pioneered by Rebecca Lancefield in the 1930s, classify beta-hemolytic streptococci into groups A through H based on carbohydrate antigens using group-specific antisera. The traditional Lancefield precipitin test involves extracting antigens via acid or enzyme treatment of bacterial suspensions, followed by reaction with antisera to form visible precipitates, confirming groups with over 98% accuracy in reference labs. Modern alternatives include latex agglutination assays, where bacterial extracts or direct colonies are mixed with latex particles coated in group-specific antibodies, yielding rapid clumping within minutes for groups A, B, C, and G with sensitivities of 95-99% and specificities exceeding 97%. These and serological approaches, while foundational, are limited by incubation times of 24-48 hours, which delay diagnosis, and reduced sensitivity (down to 70-80%) in patients pretreated with , as prior exposure can inhibit growth.

Molecular and Genomic Diagnostics

Molecular and genomic diagnostics for species leverage nucleic acid-based techniques to enable rapid, specific identification and characterization, surpassing the limitations of traditional phenotypic methods by targeting genetic markers directly from clinical samples. These approaches are particularly valuable for detecting fastidious or low-abundance streptococci in complex matrices like respiratory secretions, where conventional may fail due to prior antibiotic exposure or viability issues. Polymerase chain reaction (PCR) assays, including species-specific and multiplex formats, form the cornerstone of molecular detection for Streptococcus. For instance, primers targeting the spy gene (spy1258) in provide high specificity for Streptococcus identification, amplifying a 407 product that confirms presence in clinical isolates with over 80% sensitivity in validated studies. Similarly, multiplex PCR panels target genes like lytA for S. pneumoniae and sdaB for S. pyogenes, allowing simultaneous detection of multiple streptococcal alongside other respiratory pathogens in or samples, with amplicon sizes of 73-74 enabling real-time quantification. These assays facilitate group-level typing, such as distinguishing beta-hemolytic streptococci, and are adaptable for point-of-care use in or invasive infections. Sequencing-based methods enhance diagnostic precision through whole-genome sequencing (WGS) and (MLST). WGS of S. pneumoniae isolates accurately predicts serotypes by analyzing capsule biosynthesis loci, achieving over 95% concordance with traditional serotyping and enabling outbreak source tracking via analysis. MLST, particularly core-genome MLST (cgMLST) schemes, sequences fragments of 1,000+ housekeeping genes to assign sequence types (STs), with thresholds of <5 allelic differences identifying outbreak clusters in S. pyogenes populations, as demonstrated in surveillance of UK and Dutch isolates. These techniques support strain epidemiology without relying on phenotypic variability. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) offers rapid species-level identification by generating protein spectra from bacterial colonies, correctly classifying diverse Streptococcus isolates including S. pneumoniae and viridans group species with >90% accuracy using databases like or VITEK. For challenging cases in the Mitis or Bovis groups, it provides preliminary typing that can be confirmed by PCR or sequencing, reducing turnaround time to minutes post-culture. Recent advancements in 2024 include metagenomic enrichment via probe-based next-generation sequencing (NGS) for respiratory panels, which boosts detection of S. pneumoniae in nasopharyngeal swabs by 19.7-fold through targeted amplification of pathogen nucleic acids, identifying infections in 85% of cases where standard metagenomics yields only 73%. These molecular tools confer advantages such as detection of non-viable DNA from treated infections, identification of virulence-associated genes for risk stratification, and real-time outbreak surveillance, complementing slower culture methods in clinical settings. Their integration into syndromic panels has improved diagnostic yield for streptococcal diseases, particularly in polymicrobial respiratory contexts.

Treatment

Antibiotic Susceptibility and Therapy

Streptococci, particularly beta-hemolytic groups such as (group A Streptococcus, GAS), exhibit high susceptibility to penicillin, with minimum inhibitory concentrations (MICs) typically ≤0.12 μg/mL, and no naturally occurring resistant strains have been identified to date. Beta-lactam antibiotics remain the first-line agents for treating infections caused by non-pneumococcal streptococci due to their consistent efficacy and low resistance rates among these pathogens. Standard therapy for GAS pharyngitis involves oral penicillin V at 500 mg two to three times daily for 10 days or a single intramuscular dose of benzathine penicillin G (1.2 million units for adults), achieving bacteriological cure rates exceeding 90%. For streptococcal meningitis, intravenous (2 g every 12 hours in adults) is recommended as , with de-escalation to penicillin once susceptibility is confirmed, due to its broad coverage and favorable penetration. In patients with penicillin allergy, such as erythromycin (250 mg four times daily for 10 days) or (500 mg on day 1 followed by 250 mg daily for 4 days) serve as alternatives, though efficacy may be slightly lower owing to emerging resistance patterns. For , pneumococcal conjugate vaccines (PCVs) like PCV13 have significantly reduced the prevalence of antibiotic-resistant strains by targeting serotypes commonly associated with resistance, leading to declines in invasive infections by over 80% in vaccinated populations. Globally, resistance among pneumococcal isolates stands at approximately 30%, necessitating careful selection of alternatives like fluoroquinolones in regions with high prevalence. The 2025 Infectious Diseases Society of America (IDSA) guidelines for GAS endorse amoxicillin as the preferred oral beta-lactam (50 mg/kg/day divided twice daily for 10 days in children, up to 1 g/day in adults) over penicillin V due to improved and adherence, while maintaining penicillin as the cornerstone for susceptible strains. Resistance trends indicate stable penicillin susceptibility across streptococcal species, though vigilance for macrolide non-susceptibility is advised in selection.

Management of Resistance and Complications

Antibiotic resistance in Streptococcus species remains a significant clinical challenge, though beta-lactamase production is rare and typically not the primary mechanism of resistance; instead, alterations in mediate beta-lactam resistance in pathogens like S. pneumoniae and viridans group streptococci. resistance in group A Streptococcus (GAS), often conferred by the , has shown variable prevalence, peaking at 26-44% in invasive and non-invasive isolates during the early in certain regions. For S. pneumoniae, penicillin non-susceptibility rates exhibit global heterogeneity, ranging from 0% to over 60% in surveillance data from multiple countries, with overall resistance around 36% in recent meta-analyses. Management of resistant Streptococcus infections prioritizes alternative antibiotics with reliable activity; and are effective options for multidrug-resistant strains, including penicillin-non-susceptible S. pneumoniae and macrolide-resistant GAS, demonstrating comparable efficacy to standard therapies in clinical settings. In severe cases like caused by GAS, clindamycin is recommended adjunctively to suppress toxin production by inhibiting protein synthesis, even in strains with inducible resistance, thereby improving outcomes in animal models and human studies. Complications from Streptococcus infections, such as streptococcal (STSS), often require multimodal interventions; intravenous immunoglobulin (IVIG) serves as an adjunctive therapy in STSS by neutralizing superantigens, reducing mortality from approximately 34% to 16% in observational cohorts. For suppurative complications like abscesses in S. anginosus group or GAS infections, prompt surgical drainage is essential to remove necrotic tissue and pus collections, combined with antibiotics to achieve cure rates exceeding 90% in appropriately managed cases. Prevention of non-suppurative sequelae, such as acute (ARF) following GAS , involves vigilant post-infection monitoring with titers and for subclinical , alongside secondary prophylaxis with intramuscular benzathine penicillin G every 3-4 weeks for at least one year in affected individuals. Global surveillance efforts have intensified in the post-pandemic era, with the World Health Organization's 2025 report emphasizing real-time tracking of Streptococcus resistance patterns, noting increases in over 40% of monitored pathogen-antibiotic combinations since 2018 and calling for enhanced laboratory capacity in low-resource settings.

Prevention

Vaccination Strategies

Vaccination strategies against Streptococcus species primarily target the most clinically significant pathogens, including S. pneumoniae, S. pyogenes, and S. agalactiae, through licensed or candidates in development that aim to elicit protective immunity against invasive diseases and sequelae. These approaches leverage conjugates, protein-based formulations, or emerging technologies to address bacterial colonization and infection, with varying by pathogen due to antigenic diversity. For , the leading cause of and , pneumococcal conjugate s (PCVs) such as PCV13, PCV20, and PCV21 are widely licensed and recommended, particularly for children and adults aged ≥50 years as of the 2025 ACIP updates, demonstrating 70-90% efficacy against invasive pneumococcal disease caused by serotypes. PCV13 targets 13 serotypes and has been instrumental in reducing global disease burden through , while higher-valent versions like PCV20 (20 serotypes) and PCV21 (21 serotypes) expand coverage for adults, including those previously vaccinated with lower-valent PCVs or the PPSV23. PPSV23, a 23-valent , is approved for adults and immunocompromised individuals, offering protection against non-invasive but with lower in younger populations compared to conjugates. No licensed vaccine exists for Streptococcus pyogenes (group A Streptococcus, or GAS) as of November 2025, despite ongoing efforts to prevent , , and invasive infections, as historical candidates faced challenges in achieving broad coverage. A promising mRNA-lipid (LNP) candidate, encoding five conserved GAS antigens including M-protein derivatives and SpyAD, was reported in in July 2025, showing robust and preclinical protection in animal models against multiple serotypes; by mid-2025, it had entered phase I clinical evaluation. challenge models for Strep A were initiated in in September 2025 to accelerate testing. For (group B Streptococcus, or GBS), which causes and maternal infections, no licensed exists as of November 2025, and maternal during remains the primary strategy in development, with capsular polysaccharide-protein conjugate vaccines in phase 2 trials targeting serotypes Ia, Ib, II, III, and V to transfer antibodies to newborns. Candidates like Pfizer's GBS6 have demonstrated and safety in pregnant women, aiming to prevent early-onset GBS disease with estimated 70-80% based on surrogate endpoints. The World Health Organization's 2017 Preferred Product Characteristics (PPC) for GBS vaccines emphasize affordable maternal formulations for low-resource settings, guiding trial designs to achieve at least 80% coverage of circulating serotypes globally. Key challenges in Streptococcus vaccine development include extensive serotype diversity, which limits coverage of circulating strains—such as over 100 pneumococcal serotypes or 200+ GAS M-types—necessitating multivalent or conserved-antigen approaches. Achieving cross-protection across serotypes remains difficult, as antibodies elicited by one variant often show limited neutralization of heterologous strains, complicating and requiring ongoing surveillance of vaccine escape mutants.

Infection Prevention Measures

Basic hygiene practices, such as regular handwashing with and for at least 20 seconds and adherence to respiratory including covering coughs and sneezes with a tissue or elbow, are fundamental to reducing the transmission of Streptococcus species, particularly Group A Streptococcus (GAS) through respiratory droplets. These measures are especially critical in community settings like schools and households where close contact facilitates spread. For Streptococcus (GBS), prevention of neonatal early-onset relies on targeted clinical interventions during . Universal screening via rectal and vaginal swabs is recommended between 35 and 37 weeks of to identify maternal GBS , enabling risk-based . Positive screening results prompt intrapartum prophylaxis, typically with intravenous penicillin or alternatives for allergic individuals, which has reduced the incidence of GBS early-onset in newborns by more than 80% since the implementation of national guidelines. Outbreak control for invasive GAS infections involves prompt responses, including to identify and monitor close contacts of cases, often offering prophylaxis to high-risk individuals within 24 hours of notification. In educational settings, children diagnosed with strep throat (GAS ) are excluded from school until at least 24 hours after starting therapy to prevent further transmission. Global efforts to curb Strep A infections emphasize integrated prevention strategies tailored to low-resource settings, as outlined in the World Health Organization's ongoing roadmap initiatives updated in , which prioritize accessible diagnostics, hygiene promotion, and outbreak surveillance to address disproportionate burdens in vulnerable populations.

Genomics and Molecular Biology

Genome Structure and Variation

The genomes of Streptococcus species are typically organized as a single circular chromosome, with sizes ranging from 1.8 to 2.3 Mb and encoding approximately 1,800 to 2,200 protein-coding genes. The GC content varies between 35% and 44% across species, reflecting adaptations to different host environments and ecological niches. For instance, S. pyogenes genomes average around 1.85 Mb with 38.5% GC, while S. agalactiae strains reach up to 2.16 Mb and 35.6% GC. This compact structure supports efficient replication and metabolic versatility in diverse pathogenic and commensal contexts. The core genome of Streptococcus, conserved across strains within a species, consists of approximately 1,200 to 1,400 genes involved in essential functions such as replication, transcription, and basic . In contrast, the expands significantly due to accessory genes, often comprising 20-25% of total content and acquired through like bacteriophages and plasmids. These elements introduce intraspecies diversity, with lineage-specific genes reaching up to 21% in some analyses, enabling adaptation to host immune pressures and environmental changes without disrupting core processes. Genomic variation in Streptococcus is prominently driven by , which facilitates the integration of serotype-specific islands. A key example is the cps locus in S. pneumoniae, a variable genomic island (2-30 kb) located between the dexB and aliA genes, encoding serotype-specific enzymes for capsular synthesis that confer antigenic diversity and immune evasion. This locus exemplifies how localized recombination hotspots contribute to strain-level differences, with over 90 serotypes identified through such variations. Advances in sequencing have cataloged hundreds of Streptococcus genomes in public databases, revealing patterns of diversity across species. As of 2025, recent genomic studies on S. pyogenes have highlighted mutations in regulatory genes like covRS that enhance invasiveness, correlating with surges in severe infections and underscoring the role of ongoing variation in disease emergence.

Genetic Exchange Mechanisms

Streptococcus species employ several mechanisms for genetic exchange, enabling the acquisition of new genetic material that contributes to their adaptability and pathogenicity. These processes include bacteriophage-mediated transfer, natural transformation, and conjugation, each playing distinct roles in horizontal gene transfer within streptococcal populations. Bacteriophages, particularly temperate phages, are prominent vectors for genetic exchange in Streptococcus. In Group A Streptococcus (GAS, S. pyogenes), temperate bacteriophages commonly integrate into the bacterial genome as prophages, establishing lysogeny and conferring lysogenic conversion by carrying virulence factors such as superantigen toxins. For instance, the speC gene encoding streptococcal pyrogenic exotoxin C (SpeC), a potent superantigen implicated in toxic shock-like syndrome, is borne on temperate phages like φNIH1, which lysogenize GAS strains and enhance their pathogenic potential upon induction. Lysogeny is widespread across streptococci, with prophages in S. pneumoniae often comprising up to 10-15% of the genome and facilitating the stable inheritance of phage-encoded genes during bacterial replication. These temperate phages can excise under stress conditions, such as antibiotic exposure or host cell interactions, releasing virions that transduce genetic elements to new hosts, thereby disseminating toxin and virulence genes. Natural transformation represents another key mechanism, especially in S. pneumoniae, where cells develop competence—a transient physiological state for DNA uptake—under specific environmental cues. Competence is regulated by the Com regulon, a network of over 100 genes activated by the competence-stimulating peptide (CSP), a quorum-sensing signal that accumulates at high cell densities to synchronize population-level transformation. Recent studies have elucidated how quorum sensing integrates with stress responses, such as nutrient limitation or DNA damage, to trigger competence via the ComDE two-component system, where CSP binds the ComD receptor to induce the alternative sigma factor ComX. Transformation is less prevalent in other streptococci like GAS but occurs under similar quorum-regulated conditions. This process allows S. pneumoniae to incorporate exogenous DNA, including from lysed sibling cells, via homologous recombination of fragments typically 2-10 kb in size, with multiple events enabling significant genomic adaptation and promoting rapid adaptation. Conjugation, while rarer in core streptococci compared to enterococci, facilitates and integrative conjugative element () transfer, often conferring resistance. In streptococci such as S. anginosus and S. pneumoniae, conjugative plasmids and Tn916-like mediate direct cell-to-cell transfer of resistance genes, including erm(B) for resistance, through type IV secretion systems. These elements are mobilized at low frequencies (10^{-6} to 10^{-8} per donor cell) but enable interspecies spread, as seen in the conjugation of erm(B)-carrying from S. anginosus to related streptococci. Unlike the efficient conjugation in enterococci, streptococcal systems rely more on than broad-host-range plasmids, limiting but not eliminating resistance dissemination. This mechanism contributes to the slower of multidrug resistance in streptococci relative to . These genetic exchange mechanisms collectively drive streptococcal by introducing variability that enhances survival and . For example, in S. pneumoniae, phage-mediated transfer can facilitate switching through the packaging and transduction of capsule (cps) locus fragments, allowing evasion of host immunity and vaccines, as observed in shifts from 19A to non-vaccine types post-PCV introduction. Such exchanges underscore the role of horizontal transfer in generating diverse clones, with implications for spread and potential across Streptococcus species.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK7611/
  2. https://wwwnc.cdc.gov/eid/article/22/11/et-2211_article
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3824240/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC6287261/
  5. https://www.cdc.gov/group-a-strep/php/surveillance/index.html
  6. https://www.cdc.gov/pneumococcal/php/surveillance/index.html
  7. https://www.mdpi.com/2036-7481/16/9/194
  8. https://lpsn.dsmz.de/genus/streptococcus
  9. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/streptococcus
  10. https://www.thelancet.com/article/S1473-3099%2805%2970267-X/abstract
  11. https://my.clevelandclinic.org/health/diseases/4602-strep-throat
  12. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247%2824%2900071-5/fulltext
  13. https://journals.asm.org/doi/abs/10.1128/microbiolspec.gpp3-0042-2018
  14. https://www.nature.com/articles/s41538-024-00298-3
  15. https://academic.oup.com/cid/article-abstract/74/6/983/6311854
  16. https://www.ncbi.nlm.nih.gov/books/NBK333430/
  17. https://www.ncbi.nlm.nih.gov/books/NBK587093/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC11332154/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC2132252/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC5403050/
  21. https://pubmed.ncbi.nlm.nih.gov/30248475/
  22. https://www.microbiologyresearch.org/content/journal/ijsem/10.1099/ijsem.0.006814
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC126867/
  24. https://rupress.org/jem/article/57/4/571/10357/A-SEROLOGICAL-DIFFERENTIATION-OF-HUMAN-AND-OTHER
  25. https://www.merckmanuals.com/professional/multimedia/table/lancefield-classification
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC7696602/
  27. https://journals.asm.org/doi/10.1128/jcm.00365-12
  28. https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-025-04353-1
  29. https://www.sciencedirect.com/science/article/abs/pii/S1567134818307275
  30. https://www.microbiologyresearch.org/content/journal/ijsem/10.1099/ijsem.0.006674
  31. https://pubmed.ncbi.nlm.nih.gov/34031726/
  32. https://journals.asm.org/doi/10.1128/cmr.00058-18
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC5039425/
  34. https://journals.asm.org/doi/10.1128/jcm.01030-25
  35. https://www.ncbi.nlm.nih.gov/books/NBK554528/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC11026078/
  37. https://pneumonia.biomedcentral.com/articles/10.1186/s41479-025-00162-2
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3920295/
  39. https://www.qeios.com/read/BCSYBU.2
  40. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/streptococcus
  41. https://www.ncbi.nlm.nih.gov/books/NBK333417/
  42. https://febs.onlinelibrary.wiley.com/doi/10.1002/1873-3468.12317
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC2685916/
  44. https://www.nature.com/articles/s41522-024-00642-1
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC2738137/
  46. https://academic.oup.com/jac/article/53/2/271/850479
  47. https://pubmed.ncbi.nlm.nih.gov/17460837/
  48. https://journals.asm.org/doi/10.1128/iai.00478-23
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC6481863/
  50. https://agresearchmag.ars.usda.gov/2009/aug/strep
  51. https://pubmed.ncbi.nlm.nih.gov/32941130/
  52. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/streptococcus-thermophilus
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC242911/
  54. https://academic.oup.com/femspd/article/65/1/23/433378
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC9664950/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC6723445/
  57. https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-019-0704-8
  58. https://www.mdpi.com/2076-2607/8/11/1835
  59. https://academic.oup.com/ofid/article/10/5/ofad192/7115867
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC6023974/
  61. https://www.nature.com/articles/s41392-025-02365-x
  62. https://www.ncbi.nlm.nih.gov/books/NBK559240/
  63. https://www.ncbi.nlm.nih.gov/books/NBK587116/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC9998027/
  65. https://resou.osaka-u.ac.jp/en/research/2025/20250730_2
  66. https://www.ncbi.nlm.nih.gov/books/NBK587095/
  67. https://www.ncbi.nlm.nih.gov/books/NBK587112/
  68. https://www.nature.com/articles/s41467-025-60580-0
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC5708255/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC3375309/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC9784991/
  72. https://www.ncbi.nlm.nih.gov/books/NBK553143/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC10642950/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC5850457/
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC6432937/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC6066297/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC12259621/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC12474038/
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC8715428/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC5882794/
  81. https://www.pathologyoutlines.com/topic/microbiologystreptococcuspneumoniae.html
  82. https://www.merckmanuals.com/professional/infectious-diseases/gram-positive-cocci/pneumococcal-infections
  83. https://www.ncbi.nlm.nih.gov/books/NBK470537/
  84. https://www.cdc.gov/vaccines/vpd/pneumo/hcp/about-vaccine.html
  85. https://pneumococcalcapsules.github.io/serotypes/
  86. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0280722
  87. https://emedicine.medscape.com/article/225811-overview
  88. https://www.nature.com/articles/s41586-024-07626-3
  89. https://www.jove.com/v/51208/capsular-serotyping-streptococcus-pneumoniae-using-quellung
  90. https://www.uniprot.org/uniprotkb/P06653/entry
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC8748486/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC3032743/
  93. https://academic.oup.com/ofid/article/8/9/ofab426/6374219
  94. https://journals.asm.org/doi/10.1128/aem.02160-24
  95. https://www.tandfonline.com/doi/full/10.1038/emi.2014.45
  96. https://www.mdpi.com/2304-8158/13/9/1291
  97. https://www.merckvetmanual.com/respiratory-system/respiratory-diseases-of-horses/strangles-in-horses
  98. https://aaep.org/resource/streptococcus-equi-infectious-disease-guidelines/
  99. https://doi.org/10.1038/s41579-023-00865-7
  100. https://doi.org/10.1038/s41564-017-0005-6
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC10974102/
  102. https://doi.org/10.1016/S1473-3099(19)30446-3
  103. https://www.embopress.org/doi/10.1093/emboj/21.7.1607
  104. https://www.sciencedirect.com/science/article/abs/pii/S0966842X07002405
  105. https://www.sciencedirect.com/topics/nursing-and-health-professions/lipoteichoic-acid
  106. https://www.sciencedirect.com/science/article/pii/S094450132100135X
  107. https://www.sciencedirect.com/science/article/am/pii/S002228361930052X
  108. https://www.sciencedirect.com/org/science/article/pii/S2150751121115990
  109. https://www.sciencedirect.com/topics/immunology-and-microbiology/streptococcus-antigen
  110. https://www.sciencedirect.com/science/article/pii/S1198743X14633115
  111. https://www.nature.com/articles/s41598-018-20609-5
  112. https://www.sciencedirect.com/science/article/pii/S1369527423001571
  113. https://pubmed.ncbi.nlm.nih.gov/19001420/
  114. https://www.sciencedirect.com/science/article/pii/S0021925820438542
  115. https://pubmed.ncbi.nlm.nih.gov/39804237/
  116. https://pubmed.ncbi.nlm.nih.gov/40704999/
  117. https://www.ncbi.nlm.nih.gov/books/NBK587100/
  118. https://www.ncbi.nlm.nih.gov/books/NBK507889/
  119. https://journals.asm.org/doi/10.1128/microbiolspec.gpp3-0054-2018
  120. https://www.ncbi.nlm.nih.gov/books/NBK587091/
  121. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/necrotizing-fasciitis.html
  122. https://www.idsociety.org/practice-guideline/skin-and-soft-tissue-infections/
  123. https://emedicine.medscape.com/article/229091-overview
  124. https://www.uptodate.com/contents/group-b-streptococcal-infection-during-pregnancy
  125. https://www.ncbi.nlm.nih.gov/books/NBK534295/
  126. https://emedicine.medscape.com/article/225811-workup
  127. https://www.who.int/europe/news/item/12-12-2022-increase-in-invasive-group-a-streptococcal-infections-among-children-in-europe--including-fatalities
  128. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00051-5/fulltext
  129. https://link.springer.com/article/10.1007/s15010-025-02668-9
  130. https://wwwnc.cdc.gov/eid/article/31/9/25-0245_article
  131. https://www.ncbi.nlm.nih.gov/books/NBK333434/
  132. https://pmc.ncbi.nlm.nih.gov/articles/PMC1676147/
  133. https://www.ncbi.nlm.nih.gov/books/NBK606314/
  134. https://www.ncbi.nlm.nih.gov/books/NBK594238/
  135. https://www.ncbi.nlm.nih.gov/books/NBK538255/
  136. https://pmc.ncbi.nlm.nih.gov/articles/PMC8730744/
  137. https://www.ncbi.nlm.nih.gov/books/NBK333429/
  138. https://www.nimh.nih.gov/health/publications/pandas
  139. https://www.ncbi.nlm.nih.gov/books/NBK606088/
  140. https://pmc.ncbi.nlm.nih.gov/articles/PMC7725005/
  141. https://www.who.int/news-room/fact-sheets/detail/rheumatic-heart-disease
  142. https://www.ncbi.nlm.nih.gov/books/NBK587099/
  143. https://www.ncbi.nlm.nih.gov/books/NBK343617/
  144. https://pmc.ncbi.nlm.nih.gov/articles/PMC548093/
  145. https://pubmed.ncbi.nlm.nih.gov/4588195/
  146. https://www.cdc.gov/group-a-strep/testing/index.html
  147. https://www.idsociety.org/practice-guideline/streptococcal-pharyngitis2/
  148. https://www.idsociety.org/news--publications-new/articles/2025/idsa-releases-new-guidelines-for-diagnosing-strep-throat/
  149. https://www.ncbi.nlm.nih.gov/books/NBK587110/
  150. https://pmc.ncbi.nlm.nih.gov/articles/PMC5020175/
  151. https://pubmed.ncbi.nlm.nih.gov/19870148/
  152. https://pubmed.ncbi.nlm.nih.gov/359593/
  153. https://pmc.ncbi.nlm.nih.gov/articles/PMC193831/
  154. https://www.ncbi.nlm.nih.gov/books/NBK532209/
  155. https://pmc.ncbi.nlm.nih.gov/articles/PMC10103550/
  156. https://pmc.ncbi.nlm.nih.gov/articles/PMC7669753/
  157. https://www.scirp.org/pdf/aim_2022082515084749.pdf
  158. https://pmc.ncbi.nlm.nih.gov/articles/PMC6863929/
  159. https://pmc.ncbi.nlm.nih.gov/articles/PMC10628374/
  160. https://pmc.ncbi.nlm.nih.gov/articles/PMC6113875/
  161. https://pmc.ncbi.nlm.nih.gov/articles/PMC10662357/
  162. https://pmc.ncbi.nlm.nih.gov/articles/PMC7709296/
  163. https://www.nature.com/articles/s41598-024-75120-x
  164. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2023.1117160/full
  165. https://emedicine.medscape.com/article/228936-medication
  166. https://pmc.ncbi.nlm.nih.gov/articles/PMC7123568/
  167. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  168. https://www.uptodate.com/contents/image?imageKey=ID%252F64596
  169. https://pmc.ncbi.nlm.nih.gov/articles/PMC10215215/
  170. https://pmc.ncbi.nlm.nih.gov/articles/PMC4613642/
  171. https://www.aafp.org/pubs/afp/issues/2001/0415/p1557.html
  172. https://pmc.ncbi.nlm.nih.gov/articles/PMC6341944/
  173. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1337276/full
  174. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540525/all/Streptococcus_species
  175. https://www.mdpi.com/2079-6382/13/4/360
  176. https://pmc.ncbi.nlm.nih.gov/articles/PMC9783990/
  177. https://www.sciencedirect.com/science/article/abs/pii/S0924857923003618
  178. https://www.aafp.org/pubs/afp/issues/2002/0215/p663.html
  179. https://blog.unmc.edu/infectious-disease/2022/10/27/article-spotlight-group-a-streptococcus-emerging-antibiotic-resistance-and-treatment-options/
  180. https://www.jwatch.org/na43441/2017/02/15/why-adding-clindamycin-important-treating-group
  181. https://academic.oup.com/jid/article/215/2/269/2742472
  182. https://www.ijidonline.com/article/S1201-9712%2823%2900696-3/fulltext
  183. https://www.sciencedirect.com/science/article/pii/S1876034120305980
  184. https://emedicine.medscape.com/article/228936-treatment
  185. https://www.ahajournals.org/doi/10.1161/circulationaha.109.191959
  186. https://www.aafp.org/pubs/afp/issues/2018/0415/p517.html
  187. https://www.who.int/news/item/13-10-2025-who-warns-of-widespread-resistance-to-common-antibiotics-worldwide
  188. https://www.who.int/publications/i/item/9789240116337
  189. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/group-b-streptococcus-%28gbs%29
  190. https://www.nature.com/articles/s41541-023-00730-x
  191. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html
  192. https://www.mdpi.com/2076-393X/13/5/498
  193. https://www.cdc.gov/mmwr/volumes/74/wr/mm7401a1.htm
  194. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-025-11596-w
  195. https://pmc.ncbi.nlm.nih.gov/articles/PMC12299777/
  196. https://www.mcri.edu.au/news/news-stories/new-trial-strep-a-vaccine-development
  197. https://www.sciencedirect.com/science/article/pii/S0264410X25008722
  198. https://www.who.int/publications/i/item/WHO-IVB-17.09
  199. https://academic.oup.com/jac/article/80/5/1377/8093164
  200. https://pmc.ncbi.nlm.nih.gov/articles/PMC11435891/
  201. https://www.cdc.gov/group-a-strep/prevention/index.html
  202. https://pmc.ncbi.nlm.nih.gov/articles/PMC7926438/
  203. https://www.cdc.gov/group-b-strep/testing/index.html
  204. https://www.pregnancyinfo.ca/your-pregnancy/routine-tests/group-b-streptococcus-screening/
  205. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/02/prevention-of-group-b-streptococcal-early-onset-disease-in-newborns
  206. https://www.health.nsw.gov.au/Infectious/controlguideline/Pages/invasive-group-a-strep.aspx
  207. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/impetigo.html
  208. https://whaguide.com/events/bridging-the-gap-global-collaboration-for-group-a-streptococcus-vaccines/
  209. https://pmc.ncbi.nlm.nih.gov/articles/PMC1929146/
  210. https://pmc.ncbi.nlm.nih.gov/articles/PMC11091432/
  211. https://elifesciences.org/articles/101938
  212. https://journals.asm.org/doi/10.1128/microbiolspec.gpp3-0059-2018
  213. https://www.sciencedirect.com/science/article/abs/pii/S0378109703000223
  214. https://www.mdpi.com/2076-2607/8/10/1546
  215. https://www.sciencedirect.com/science/article/pii/S0923250800001716
  216. https://pmc.ncbi.nlm.nih.gov/articles/PMC11811101/
  217. https://journals.asm.org/doi/10.1128/mbio.01394-25
  218. https://www.liebertpub.com/doi/10.1089/mdr.2023.0342
  219. https://journals.asm.org/doi/10.1128/spectrum.03759-22
  220. https://journals.asm.org/doi/10.1128/microbiolspec.arba-0008-2017
  221. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2018.02580/full
  222. https://www.nature.com/articles/s41467-024-49853-2
Add your contribution
Related Hubs
User Avatar
No comments yet.